Phosphodiesterase 4 · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Phosphodiesterase 4 shows approved-linked disease relevance led by chronic obstructive pulmonary disease. 5 more disease programs remain visible in the same review block. 10 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P27815. Start with chronic obstructive pulmonary disease, then reuse UniProt P27815 as the stable protein anchor across project notes and exports.
Start with chronic obstructive pulmonary disease, then reuse UniProt P27815 as the stable protein anchor across project notes and exports.
Phosphodiesterase 4 shows approved-linked disease relevance led by chronic obstructive pulmonary disease. 5 more disease programs remain visible in the same review block. 10 linked drugs remain visible in the same block.
Start review with chronic obstructive pulmonary disease because it currently carries approved-linked support. Linked drugs include CILOMILAST, ENSIFENTRINE, GSK-256066, MK-0873. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxy3',5'-cyclic-AMP phosphodiesterase 4A
Review this target as Phosphodiesterase 4, mapped to UniProt P27815. ChEMBL maps the protein component as 3',5'-cyclic-AMP phosphodiesterase 4A. Sequence length is 886 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Phosphodiesterase 4 as ChEMBL target CHEMBL2093863, mapped to UniProt P27815. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Phosphodiesterase 4 is the right protein anchor across sources, using UniProt P27815 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why chronic obstructive pulmonary disease is currently framed as approved-linked support. It currently carries 10 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Phosphodiesterase 4 |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | P27815 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | 3',5'-cyclic-AMP phosphodiesterase 4A |
| UniProt Accession | P27815 |
| Component Type | Protein |
| Sequence Length | 886 aa |
3',5'-cyclic-AMP phosphodiesterase 4A
Review this target as Phosphodiesterase 4, mapped to UniProt P27815. ChEMBL maps the protein component as 3',5'-cyclic-AMP phosphodiesterase 4A. Sequence length is 886 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Phosphodiesterase 4 shows approved-linked disease relevance led by chronic obstructive pulmonary disease. 5 more disease programs remain visible in the same review block.
Start review with chronic obstructive pulmonary disease because it currently carries approved-linked support. Linked drugs include CILOMILAST, ENSIFENTRINE, GSK-256066, MK-0873. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3113974 | 10.59 | IC50 | 0.026 | Clinical |
| CHEMBL3968147 | 10.52 | IC50 | 0.03 | Preclinical |
| CHEMBL3113966 | 10.52 | IC50 | 0.03 | Preclinical |
| CHEMBL3113954 | 10.52 | IC50 | 0.03 | Preclinical |
| CHEMBL3113949 | 10.52 | IC50 | 0.03 | Preclinical |
| CHEMBL3113948 | 10.52 | IC50 | 0.03 | Preclinical |
| CHEMBL3113976 | 10.4 | IC50 | 0.04 | Preclinical |
| CHEMBL3113968 | 10.4 | IC50 | 0.04 | Preclinical |
| CHEMBL3113962 | 10.4 | IC50 | 0.04 | Preclinical |
| CHEMBL3113943 | 10.4 | IC50 | 0.04 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein format | 292 | 1,230 | 6.5 |
| cell-based format | 49 | 370 | 7.0 |
| assay format | 15 | 66 | 7.1 |
| tissue-based format | 10 | 96 | 5.5 |
| cell membrane format | 2 | 44 | 7.0 |
| subcellular format | 1 | 2 | 8.8 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| organism-based format | 9 | 0 | — |
| assay format | 4 | 14 | 5.7 |
| tissue-based format | 4 | 20 | 8.7 |
| cell-free format | 2 | 0 | — |
| cell-based format | 1 | 47 | 5.9 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 0 | — |
| protein format | 1 | 2 | 5.5 |